Laddar...
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurof...
Sparad:
| I publikationen: | Biomark Res |
|---|---|
| Huvudupphovsman: | |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8052700/ https://ncbi.nlm.nih.gov/pubmed/33863389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-021-00281-0 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|